Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor × Dacarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 40 Hodgkin Disease 6 Neoplasms 5 Neoplasm Metastasis 5 Leiomyosarcoma 5 Skin Neoplasms 4 Sarcoma 3 Lymphoma 2 Uveal Melanoma 1 Solid Tumor 1 Skin Diseases 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Melanoma Neoplasms 1 Lung Neoplasms 1 Liposarcoma 1 Kidney Neoplasms 1 Hematologic Diseases 1 Colonic Neoplasms 1 Carcinoma 1 Breast Neoplasms 1 Advanced Melanoma 1

Interventions

Injections 11 pembrolizumab 9 Paclitaxel 8 senaparib 7 Docetaxel 7 Nivolumab 6 Cisplatin 5 Capecitabine 5 toripalimab 4 atezolizumab 4 Ipilimumab 4 Gemcitabine 4 tislelizumab 3 Rifampin 3 Itraconazole 3 Carboplatin 3 Bevacizumab 3 130-nm albumin-bound paclitaxel 3 zimberelimab 2 sintilimab 2 pertuzumab 2 ontuxizumab 2 magrolimab 2 fluzoparib 2 famitinib 2 durvalumab 2 camrelizumab 2 alpha-Synuclein 2 Oxaliplatin 2 Midazolam 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡